A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

NCT07719855 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

652

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma ( FL)

Interventions

DRUG: Orelabrutinib
DRUG: obinutuzumab
DRUG: Lenalidomide
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone
DRUG: Vincristine
DRUG: Bendamustine

Sponsor

Ruijin Hospital